Business Context and Reporting Period
This Form 6-K filing by Smith & Nephew plc (LSE:SN, NYSE:SNN) is dated September 10, 2026. The company is a portfolio medical technology business focused on the repair, regeneration, and replacement of soft and hard tissue, operating in approximately 100 countries with 17,000 employees. The filing announces the pricing of a new bond issue rather than reporting operational financial results for a specific period.
Key Financial Metrics
The filing details a specific debt financing transaction rather than providing comprehensive income statement or cash flow metrics for the period.
- New Debt Issuance: USD 700,000,000 in 5.750% Notes due 2036.
- Net Proceeds: USD 690,928,000 (after underwriting discounts).
- Historical Revenue: The company generated annual sales of USD 6.2 billion in 2025.
- Other Metrics: The filing text does not provide clear values for current period revenue, profit, operating margins, free cash flow, or total debt levels outside of the specific bond transaction.
Material Changes and Transaction Details
The primary material change is the execution of a debt refinancing strategy. The proceeds from the new 2036 Notes will be utilized to fund a tender offer for the company's outstanding 2.032% Senior Notes due 2030. The remaining proceeds will be allocated to paying related fees and expenses and for general corporate purposes. The offering is scheduled to close on September 11, 2026, subject to customary conditions.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding expected revenue growth, trading profit margins, and market trends but does not provide specific numerical guidance or updated outlook figures. Management highlights numerous risks that could cause actual results to differ materially from expectations, including:
- Geopolitical conflicts in Europe and the Middle East.
- Economic conditions affecting healthcare providers and payers.
- Regulatory approvals, reimbursement decisions, and government actions.
- Product defects, recalls, or quality management system failures.
- Supply chain disruptions and cybersecurity threats.
- Foreign exchange volatility and changes in taxation regulations.
Investor Verification Checklist
- Verify the final closing of the USD 700 million bond issuance on September 11, 2026.
- Confirm the success and final terms of the tender offer for the 2.032% Senior Notes due 2030.
- Review the full prospectus filed with the SEC for detailed risk factors and use of proceeds.
- Monitor the company's most recent Form 20-F (year ended December 31, 2025) and interim Form 6-K (six months ended June 27, 2026) for comprehensive financial performance data not included in this announcement.